CXCRs (CXC chemokine receptors) are membrane-integral proteins that bind and react to particular members of the CXC chemokine family of cytokines. They belong to a large family of G protein-linked receptors known as seven transmembrane (7-TM) proteins because they span the cell membrane seven times. They are one subfamily of chemokine receptors. CXCR1 through CXCR7 are the seven CXC chemokine receptors that are currently recognized in mammals.The CXC chemokine receptors CXCR1 and CXCR2 recognize CXC chemokines that have an E-L-R amino acid motif right next to their CXC motif. The majority of CXCR3-expressing cells are T lymphocytes. Like CCR5, CXCR4 is the receptor for a chemokine called CXCL12 (also known as SDF-1), and it is used by HIV-1 to enter target cells.The B cell-specific chemokine receptor CXCR5 plays a role in lymphocyte homing and the maturation of healthy lymphoid tissue. Prior to being given the name CXCR6, CXCR6 was known by three different names (STRL33, BONZO, and TYMSTR) because of its chromosomal location and similarity to other chemokine receptors in its gene sequence. CXCR7 was previously known as RDC-1 (an orphan receptor), but after it was discovered that CXCL12 (the ligand for CXCR4) causes chemotaxis in T lymphocytes, this molecule was renamed to CXCR7.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V51669 | Plerixafor-d4 | 1246819-87-3 | deuterium labeled Plerixafor |
|
V51665 | Polyphemusin II-Derived Peptide | 229030-20-0 | Polyphemusin II-Derived Peptide (T140) is a CXCR4 conjugate that displays high inhibitory effect against HIV-1 entry, as well as anti-CXCR4 monoclonal antibody (mAb) (12G5) conjugated to CXCR4. |
|
V13316 | PS372424 HCl | 914291-61-5 | PS372424 (PS-372424) HCl is a novel and potent agonist of CXCR3 with anti-inflammatory activity. |
|
V74886 | PS372424 hydrochloride | 1596362-29-6 | PS372424 HCl, a three-amino acid (AA) fragment of CXCL10, is a specific human CXCR3 agonist/activator with anti-inflammatory activity. |
|
V74882 | Quetmolimab | 2084037-83-0 | Quetmolimab is a humanized monoclonal antibody (mAb) against chemokine ligand 1 (CX3CL1). |
|
V3794 | Reparixin | 266359-83-5 | Reparixin (also known as Repertaxin), is a novel, potent small molecular weight allosteric inhibitor of chemokine receptor 1/2 (CXCR1/2) activation. |
|
V3793 | Reparixin L-lysine salt | 266359-93-7 | Reparixin L-lysine salt, the L-lysine salt form of reparixin, is a novel, potent small molecule weight allosteric inhibitor of chemokine receptor 1/2 (CXCR1/2) activation. |
|
V1490 | SB225002 | 182498-32-4 | SB225002 (SB 225002; SB-225002) is a novel, potent, and selective non-peptide antagonist of chemokine receptor CXCR2 with potential anti-inflammatory activity. |
|
V3795 | SCH 563705 | 473728-58-4 | SCH-563705 (SCH563705) is a novel potent and orally bioactive antagonist of CXCR2 and CXCR1 with anti-Inflammatory and immunomodulatory activity. |
|
V74884 | SDF-1α (human) | 1268129-65-2 | SDF-1α (human) is a monocyte chemotactic agent that binds to the CXCR4 receptor. |
|
V3798 | SRT3109 | 1204707-71-0 | SRT3109 (SRT-3109) is a novel and potent antagonist of CXCR2 (C-X-C chemokine receptor type 2) with potential anti-Inflammatory and immunomodulatory activity. |
|
V3797 | SRT3190 | 1204707-73-2 | SRT3190 (SRT-3190) is a potent and selective antagonist of CXCR2 (C-X-C chemokine receptor type 2) and an activator of SIRT1 with anti-Inflammatory and immunomodulatory activity. |
|
V3258 | SX-682 | 1648843-04-2 | SX-682 (SX682) is a novel boronic acid-containing and selective CXCR2 chemokine receptor antagonist with potential anticancer and immunomodulatory activities. |
|
V51666 | TC-14012 | 368874-34-4 | peptidomimetic inverse CXCR4 agonist |
|
V51653 | Ulocuplumab (BMS-936564; MDX-1338) | 1375830-34-4 | Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. |
|
V27842 | UNBS5162 | 956590-23-1 | UNBS5162 is a novel naphthalimide that binds to DNA by intercalation and suppresses CXCL chemokine elaboration. |
|
V27884 | USL311 | 1373268-67-7 | USL311 is a novel, selective and potent CXCR4 receptor antagonist with anticancer activity by disrupting the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4, which prevents CXCR4 activation and decreases proliferation and migration of CXCR4-expressing tumor cells. |
|
V51670 | Vimnerixin (AZD4721; RIST4721) | 1418112-77-2 | Vimnerixin (AZD4721) is a potent and proximal-active antagonist of the acidic CXC chemokine receptor 2 (CXCR2). |
|
V51667 | vMIP-II (1-21) [NT21MP; V1 peptide] | 265650-93-9 | vMIP-II (1-21) is an antagonist of CXCR4. |
|
V37644 | VUF11207 fumarate | 1785665-61-3 | VUF11207 fumarate is a novel, selective and highly potent agonist of CXCR7 (pKi of 8.1) , inducing the recruitment of β-arrestin2 (pEC50 of 8.8) and subsequent internalization (pEC50 of 7.9) of CXCR7. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
